N
Nuklex AB
● Website: nuklex.se
Grade B
↗
Growing
Based on score analysis
€1M - €5M
Revenue (2025)
Negative
Net Income
B
Grade
Get notified when score changes
Risk Overview
● Revenue: Stable
● Profitability: Loss-making
● Status: active
Key People
Executive data not available. Get Enterprise Report →
Corporate Structure
→ Nuklex AB (this company)
Corporate group data requires LEI. Get Enterprise Report →
Top Competitors
Companies in the same sector and revenue range
| Company | Revenue | Employees | Score |
|---|---|---|---|
| Nuklex AB | €1M - €5M | N/A | 65 |
| GE Healthcare Bio-Sciences AB | > €1B | 1,000+ | 65 |
| GE Healthcare BioProcess R&D AB | > €1B | N/A | 65 |
| Phadia AB | €100M - €1B | N/A | 65 |
| Fresenius Kabi AB | €100M - €1B | 250-1,000 | 65 |
| Q-Med Aktiebolag | €100M - €1B | N/A | 65 |
Certifications & Standards
No certifications on record. Claim this profile to add certifications (ISO 9001, ISO 14001, SOC 2, etc.).
Credit Worthiness
Fair
Acceptable financial standing
Latest News
Loading...
Company Details
| Tax ID / VAT | 556569-1721 |
| LEI | 5493000FFPVDEGP74849 |
| Legal Form | XJHM |
| Source | gleif.org,allabolag.se |
Company Timeline
Last Financial Report2025
Score Updated2026-05-24
Website preview — nuklex.se
Financial Summary
| Revenue | €1M - €5M |
| Net Income | Negative |
| Financial Year | 2025 |
Full Financial Report
See what is included in each plan
Exact revenue, profit, employees, 6-year trend, sector benchmark
Similar Companies in Uppsala
Company Reviews
No reviews yet. Be the first to review →